Published in Managed Care Law Weekly, March 5th, 2006
Fast Track designation is reserved for new drugs that demonstrate the potential to address a significant unmet medical need and are intended for the treatment of a serious or life-threatening condition.
In citing reasons for granting the Fast Track designation, the agency noted that current approved treatments for PAD do not target underlying incipient contributors to disease progression, thought to be related to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Managed Care Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.